AndroMETa-CRC-064
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
- NCT06614192 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built an HCP commentary report on AndroMETa-CRC-064 (telisotuzumab adizutecan in Metastatic Colorectal Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AndroMETa-CRC-064 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Telisotuzumab Adizutecan
- Arms
- Telisotuzumab Adizutecan Dose A · Experimental
- Telisotuzumab Adizutecan Dose B · Experimental
- Enrollment
- 74
- Primary outcomes
- Percentage of Participants with Adverse Events (AE)s
- Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator
- Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator
- Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator
- Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- AbbVie
- Start
- Nov 8, 2024
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06614192 · updated Sep 23, 2026